Washington, D.C.’s medical cannabis program recorded $7.8 million in total sales in September, reflecting a slight 5% decline from August, consistent with the program’s historical trend of slower fall months, according to the city’s monthly metric report. Dispensary sales fell 4%, while the number of patients served dropped just over 3.5%, and average purchase amounts continued a gradual decline across patient types.
Despite the overall dip, certain segments showed strong growth. Manufacturing sales nearly quadrupled year-over-year to $2,066,572, while cultivation sales decreased almost 15% to $528,178. Total amounts sold increased for concentrates, infused concentrates, infused pre-rolls, infused topicals, raw pre-rolls, and shake/trim. Concentrate sales alone grew over 38%, totaling 359 grams.
Most out-of-District patients continued to come from Maryland, Virginia, and Florida. Revenue fell for nearly all product categories except infused pre-rolls, raw pre-rolls, and infused topicals, highlighting shifts in patient preferences amid ongoing market adjustments following the federal takeover earlier this year.
September in short
- Total market sales: $7.8 million, down about 5% from August.
- Dispensary sales: Fell 4% from the previous month.
- Patients served: Dropped just over 3.5%.
- Average sale per patient: Gradually declining.
- Top out-of-District patient residencies: Maryland, Virginia, Florida.
- Manufacturing sales: $2,066,572; nearly quadrupled from September 2024.
- Cultivation sales: $528,178; down about 15% from September 2024.
- Revenue fell for most products except: infused pre-rolls, raw pre-rolls, infused topicals.
- Total amounts sold increased for: concentrate, infused concentrate, infused pre-rolls, infused topicals, raw pre-rolls, shake/trim.
- Concentrate sales: Grew 38% by weight (359g).
